Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $14.14 million. The enterprise value is $7.25 million.
Important Dates
The next estimated earnings date is Wednesday, April 15, 2026, before market open.
| Earnings Date | Apr 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 7.99 million shares outstanding. The number of shares has increased by 570.57% in one year.
| Current Share Class | 7.99M |
| Shares Outstanding | 7.99M |
| Shares Change (YoY) | +570.57% |
| Shares Change (QoQ) | +51.50% |
| Owned by Insiders (%) | 10.79% |
| Owned by Institutions (%) | 8.65% |
| Float | 3.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.80 |
| Forward PS | n/a |
| PB Ratio | 2.62 |
| P/TBV Ratio | 6.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.22
| Current Ratio | 1.22 |
| Quick Ratio | 1.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1,059.63% and return on invested capital (ROIC) is -785.48%.
| Return on Equity (ROE) | -1,059.63% |
| Return on Assets (ROA) | -92.29% |
| Return on Invested Capital (ROIC) | -785.48% |
| Return on Capital Employed (ROCE) | -346.47% |
| Weighted Average Cost of Capital (WACC) | 13.91% |
| Revenue Per Employee | $406,571 |
| Profits Per Employee | -$1.31M |
| Employee Count | 7 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.69% in the last 52 weeks. The beta is 1.76, so Traws Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.76 |
| 52-Week Price Change | -35.69% |
| 50-Day Moving Average | 1.78 |
| 200-Day Moving Average | 1.86 |
| Relative Strength Index (RSI) | 52.93 |
| Average Volume (20 Days) | 95,377 |
Short Selling Information
The latest short interest is 526,505, so 6.59% of the outstanding shares have been sold short.
| Short Interest | 526,505 |
| Short Previous Month | 505,708 |
| Short % of Shares Out | 6.59% |
| Short % of Float | 13.87% |
| Short Ratio (days to cover) | 0.15 |
Income Statement
In the last 12 months, Traws Pharma had revenue of $2.85 million and -$9.16 million in losses. Loss per share was -$1.38.
| Revenue | 2.85M |
| Gross Profit | 2.85M |
| Operating Income | -15.79M |
| Pretax Income | -13.31M |
| Net Income | -9.16M |
| EBITDA | -15.77M |
| EBIT | -15.79M |
| Loss Per Share | -$1.38 |
Full Income StatementBalance Sheet
The company has $6.42 million in cash and n/a in debt, with a net cash position of $6.42 million or $0.80 per share.
| Cash & Cash Equivalents | 6.42M |
| Total Debt | n/a |
| Net Cash | 6.42M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 4.55M |
| Book Value Per Share | 0.64 |
| Working Capital | 1.74M |
Full Balance SheetCash Flow
| Operating Cash Flow | -19.47M |
| Capital Expenditures | n/a |
| Free Cash Flow | -19.47M |
| FCF Per Share | -$2.44 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -554.64% |
| Pretax Margin | -467.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Traws Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -570.57% |
| Shareholder Yield | -570.57% |
| Earnings Yield | -67.00% |
| FCF Yield | -142.46% |
Analyst Forecast
The average price target for Traws Pharma is $8.00, which is 351.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 351.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 220.82% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 23, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Sep 23, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Traws Pharma has an Altman Z-Score of -73.92 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -73.92 |
| Piotroski F-Score | 2 |
